The abstract is read at the publisher; the summary is JClub's.
Upadacitinib 15 mg once daily did not significantly delay time to first relapse in Takayasu arteritis in SELECT-TAK (hazard ratio 0·52, p=0·045).
- Why it matters: Patients with Takayasu arteritis still need steroid-sparing immunosuppressive options that help maintain remission after failed glucocorticoid tapering.
- What they did: In a phase 3, multicentre double-blind trial across 31 sites in six countries, 59 eligible adults were randomized 1:1 to upadacitinib or placebo, with glucocorticoid taper starting at week 4.
- The result: Median time to relapse was 107·9 weeks with upadacitinib versus 20·1 weeks with placebo, but the primary endpoint was not met; serious adverse events were 9 vs 4 with no deaths.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.